Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 4, 2011, Pages 434-442

  Longenberger, Justin ^a   Shah, Zahoor A ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Cholesterol; Dementia; HMG CoA reductase inhibitors

Indexed keywords

AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT; ATORVASTATIN; BETA SECRETASE 1; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYL BETA CYCLODEXTRIN; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMPARATIVE STUDY; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG HALF LIFE; EPISODIC MEMORY; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BRAIN LEVEL; LONG TERM CARE; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPATIAL MEMORY; TREATMENT DURATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; CHOLESTEROL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SIMVASTATIN;

EID: 79959348158     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511795745393     Document Type: Review

References (47)

1. Hoglund K, Blennow K. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs 21(6): 449-62 (2007).
2. Mohandas E, Rajmohan V, Raghunath B. Neurobiology of Alzheimer's disease. Indian J Psychiatry 51(1): 55-61 (2009).
3. Li L, Cao D, Kim H, Lester R, Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60(6): 729-39 (2006).
4. Xu X. Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J Alzheimers Dis 16(2): 211-24 (2009).
5. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34(2): 335-7 (2003).
6. Atamna H, Frey WH, Ko N. Human and rodent amyloid-beta peptides differentially bind heme: relevance to the human susceptibility to Alzheimer's disease. Arch Biochem Biophys 487(1): 59-65 (2009).
7. Chauhan NB. Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. J Lipid Res 44(11): 2019-29 (2003).
8. Morell P, Jurevics H. Origin of cholesterol in myelin. Neurochem Res Apr 21(4): 463-70 (1996).
9. Paschen W. Glutamate excitotoxicity in transient global cerebral ischemia. Acta Neurobiol Exp (Wars) 56(1): 313-22 (1996).
10. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 7: 97 (2009).
11. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 8(3): E606-21 (2006).
12. Miyazaki I, Asanuma M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 62(3): 141-50 (2008).
13. Ogawa N. Factors affecting levodopa effects in Parkinson's disease. Acta Med Okayama 54(3): 95-101 (2000).
14. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390(3): 191-214 (2009).
15. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281(16): 10816-10824 (2006).
16. Sultana R, Perluigi M, Butterfield DA. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118(1): 131-150 (2009).
17. Huang Q, Aluise CD, Joshi G, Sultana R, St Clair DK, Markesbery WR, et al. Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. J Neurosci Res 88 (12): 2618-2629 (2010).
18. Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 17(9): 641-652 (2003).
19. Starkstein SE, Sabe L, Petracca G, Chemerinski E, Kuzis G, Merello M, et al. Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. J Neurol Neurosurg Psychiatry 61(4): 381-387 (1996).
20. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 16(2): 184-91 (2001).
21. Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol Scand Suppl 185: 43-49 (2006).
22. Morley JE, Banks WA. Lipids and Cognition. J Alzheimers Dis 20 (3): 737-747 (2010).
23. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322(7300): 1447-1451 (2001).
24. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68(10): 751-756 (2007).
25. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28(1): 75-80 (2009).
26. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346):1623-1630 (2002).
27. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 15(6): 426-32 (1992).
28. Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem 78: 1017-40 (2009).
29. Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J Clin Pharmacol 46(7): 812-816 (2006).
30. Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 7(3): 167-85 (2009).
31. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98(10): 5856-5861 (2001).
32. Murphy MP, Morales J, Beckett TL, Astarita G, Piomelli D, Weidner A, et al. Changes in Cognition and Amyloid-beta Processing with Long Term Cholesterol Reduction using Atorvastatin in Aged Dogs. J Alzheimers Dis Aug 30: (2010).
33. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 24(5): 637-643 (2003).
34. Abrahamson EE, Ikonomovic MD, Dixon CE, DeKosky ST. Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann Neurol 66(3): 407-414 (2009).
35. Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 35(3): 406-14 (2009).
36. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10): 1439-1443 (2000).
37. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 23(1-2): 94-8 (2004).
38. Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61(3): 333-3337 (2004).
39. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62(7): 1047-1051 (2005).
40. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62(5): 753-757 (2005).
41. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis 13(2): 187-197 (2008).
42. Hyttinen L, Tuulio-Henriksson A, Vuorio AF, Kuosmanen N, Harkanen T, Koskinen S, et al. Long-Term Statin Therapy is Associated with Better Episodic Memory in Aged Familial Hypercholesterolemia Patients in Comparison with Population Controls. J Alzheimers Dis Jun 21: (2010).
43. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 76(12): 1624-1629 (2005).
44. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62(2): 217-24 (2005).
45. Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 62(4): 259-65 (2006).
46. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 21(1): 95-102 (2010).
47. Banks WA. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease. BMC Neurosci 9 Suppl 3:S2 (2008).